Latest Hotspot

Innate Pharma's Lacutamab Clinical Program resumes with FDA's approval after lifting previous partial hold

10 January 2024
3 min read

Innate Pharma SA has made public that the United States' Food and Drug Administration (FDA) has removed the partial hold previously enforced on the Investigational New Drug application for lacutamab. This announcement, made on October 5, indicated that FDA had partially suspended the lacutamab IND in response to a mortality that occurred in the context of the TELLOMAK trial. Initially, the death was associated with complications arising from hemophagocytic lymphohistiocytosis, which is an uncommon blood-related condition and impacted a patient suffering from Sézary syndrome.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The authorization from the FDA to remove the clinical hold in part can be attributed to an evaluation of a mortality incident by the FDA, which Innate and an autonomous advisory group of specialists concluded was due to the rapid worsening of the condition, not associated with the administration of lacutamab.

"In close collaboration with the FDA, we have meticulously worked through the resolution process of the partial clinical hold placed on the lacutamab Investigational New Drug application, which necessitated a comprehensive examination of the fatality attributed to an advanced stage of the illness," stated Dr. Quaratino, the Chief Medical Officer at Innate Pharma.

Dr. Quaratino also mentioned, "Post the positive disclosures on Sézary syndrome at the latest ASH Annual Meeting 2023, the lacutamab initiative is progressing according to our strategic schedule. We eagerly anticipate the occasion to present comprehensive results for Mycosis Fungoides."

Lacutamab stands out as a novel therapeutic agent classified as an anti-KIR3DL2 humanized antibody with the capability to induce cytotoxicity. It's being investigated clinically as a potential therapy option for certain lymphomas, specifically cutaneous T-cell lymphoma—a disease recognized as orphan due to its rarity—and peripheral T cell lymphoma. These uncommon forms of cutaneous lymphoma, originating in T cells, typically carry a dire outlook and have limited treatment alternatives that are both effective and low-risk, especially at later stages.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of January 10, 2024, there are 2 investigational drugs for the KIR3DL2 target, including 9 indications, 2 R&D institutions involved, with related clinical trials reaching 5, and as many as 702 patents.

Lacutamab is granted European Medicines Agency PRIME designation and US Food and Drug Administration granted Fast Track designation for the treatment of patients with relapsed or refractory Sézary syndrome who have received at least two prior systemic therapies. Lacutamab is granted orphan drug status in the European Union and in the United States for the treatment of CTCL.

图形用户界面, 文本

描述已自动生成

Why is it important to strictly follow the protocol of clinical trials?
Knowledge Base
2 min read
Why is it important to strictly follow the protocol of clinical trials?
10 January 2024
Now the new regulation stresses that the old version of the test documents should be kept and indicated with expiration date.
Read →
Avenzo Therapeutics unveils promising CDK2 inhibitor AVZO-021, originally from Allorion Therapeutics
Latest Hotspot
3 min read
Avenzo Therapeutics unveils promising CDK2 inhibitor AVZO-021, originally from Allorion Therapeutics
10 January 2024
Avenzo Therapeutics has disclosed the promising clinical phase CDK2 inhibitor known as AVZO-021, originally developed by Allorion Therapeutics.
Read →
Who should be responsible for the statistical analysis of clinical trials?
Knowledge Base
2 min read
Who should be responsible for the statistical analysis of clinical trials?
10 January 2024
Upon trial completion, the supervisor will retrieve the original case report form's first page, followed by data entry into the database for statistical analysis by the biostatistician per the pre-trial plan.
Read →
Inspirna partners with German Merck KGaA to accelerate global development of RGX-202, also called Ompenaclid
Latest Hotspot
4 min read
Inspirna partners with German Merck KGaA to accelerate global development of RGX-202, also called Ompenaclid
9 January 2024
Inspirna teams up with German-based Merck KGaA to expedite the worldwide advancement of the drug Ompenaclid, known as RGX-202
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.